drugset
drugset / Trial / NCT00062205

Imatinib Mesylate in Treating Patients With Recurrent Ewing's Family of Tumors or Desmoplastic Small Round-Cell Tumor

NCT00062205 ↗

Phase 2 Completed 40 enrolled City of Hope Medical Center National Cancer Institute (NCI) · collab
Open-labelTreatment

Summary

RATIONALE: Imatinib mesylate may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. PURPOSE: This phase II trial is studying how well imatinib mesylate works in treating patients with recurrent Ewing's family of tumors or desmoplastic small round-cell tumor.

Timeline

Start
2002-06
Primary completion
2007-06
Completion
2007-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Imatinib Small molecule — Oral

Indications

sarcoma